NEPENTHE - Next Generation Personalized Neuroblastoma Therapy

NEPENTHE - Next Generation Personalized Neuroblastoma Therapy

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description
This is a clinical trial for patients with neuroblastoma that has returned (relapsed) or has not responded to standard treatment. The patients will have a biopsy of their tumor that will be tested for genetic changes and then matched to available drugs. If the results from the testing show molecular features in the tumor that allow for study treatment, patients will be invited for further testing to see if they are eligible for new treatments. Experimental therapies are all taken orally and may consist of one drug or a combination of drugs

Eligibility and criteria
IRB Number:
14-011071
Eligible age range:
Any years - Any years
Clinical trial phase:
Phase I
Phase II
Official title:
NEPENTHE: Next Generation Personalized Neuroblastoma Therapy

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.